David Waterhouse

21.7k total citations
175 papers, 4.9k citations indexed

About

David Waterhouse is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, David Waterhouse has authored 175 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Oncology, 81 papers in Pulmonary and Respiratory Medicine and 26 papers in Cancer Research. Recurrent topics in David Waterhouse's work include Lung Cancer Treatments and Mutations (60 papers), Lung Cancer Research Studies (36 papers) and Cancer Immunotherapy and Biomarkers (31 papers). David Waterhouse is often cited by papers focused on Lung Cancer Treatments and Mutations (60 papers), Lung Cancer Research Studies (36 papers) and Cancer Immunotherapy and Biomarkers (31 papers). David Waterhouse collaborates with scholars based in United States, United Kingdom and Netherlands. David Waterhouse's co-authors include David R. Spigel, John D. Hainsworth, Howard A. Burris, Ronald B. Natale, Stephen A. Ward, F. Anthony Greco, Robert C. Whorf, Coleman K. Obasaju, Mary Varterasian and Oday Hamid and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

David Waterhouse

162 papers receiving 4.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Waterhouse United States	35	2.5k	2.0k	1.3k	720	480	175	4.9k
Rupert Bartsch Austria	42	3.4k 1.4×	2.2k 1.1×	837 0.6×	1.1k 1.5×	411 0.9×	275	5.8k
Yu Jung Kim South Korea	35	2.5k 1.0×	1.6k 0.8×	1.0k 0.8×	729 1.0×	359 0.7×	247	5.1k
E. Anders Kolb United States	46	1.8k 0.7×	1.4k 0.7×	3.1k 2.3×	919 1.3×	511 1.1×	283	6.2k
Sébastien J. Hotte Canada	41	2.9k 1.2×	2.7k 1.4×	2.5k 1.8×	1.3k 1.8×	416 0.9×	250	6.6k
Joshua D. Schiffman United States	38	1.3k 0.5×	1.4k 0.7×	2.3k 1.7×	1.4k 1.9×	553 1.2×	155	6.2k
Salomon M. Stemmer Israel	46	5.0k 2.0×	1.6k 0.8×	2.0k 1.5×	1.7k 2.3×	535 1.1×	237	8.5k
Linda Mileshkin Australia	40	3.2k 1.3×	938 0.5×	1.6k 1.2×	979 1.4×	885 1.8×	273	6.6k
Rebecca Slack United States	32	1.5k 0.6×	846 0.4×	1.0k 0.8×	628 0.9×	406 0.8×	101	3.8k
Thomas John Australia	39	3.2k 1.3×	3.7k 1.9×	1.7k 1.2×	1.1k 1.5×	331 0.7×	260	6.0k
Susan F. Slovin United States	46	3.2k 1.3×	2.8k 1.4×	2.1k 1.6×	719 1.0×	277 0.6×	202	7.1k

Countries citing papers authored by David Waterhouse

Since Specialization

Citations

This map shows the geographic impact of David Waterhouse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Waterhouse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Waterhouse more than expected).

Fields of papers citing papers by David Waterhouse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Waterhouse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Waterhouse. The network helps show where David Waterhouse may publish in the future.

Co-authorship network of co-authors of David Waterhouse

This figure shows the co-authorship network connecting the top 25 collaborators of David Waterhouse. A scholar is included among the top collaborators of David Waterhouse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Waterhouse. David Waterhouse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Waterhouse, David, et al.. (2025). Real-world treatment patterns, healthcare resource utilization, and healthcare costs in patients in the United States with metastatic non-small cell cancer receiving second or subsequent line systemic anticancer therapy. Respiratory Medicine and Research. 88. 101197–101197.

Lan, Zhiyi, David Waterhouse, Jürgen Wolf, et al.. (2025). Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation. Advances in Therapy. 42(9). 4300–4317.

Butrynski, James E., John C. Paschold, Patrick J. Ward, et al.. (2024). Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium.. Journal of Clinical Oncology. 42(16_suppl). 8047–8047. 1 indexed citations

Waterhouse, David, et al.. (2024). Abstract 3819: Real-world long-term survival outcomes of first-line immunotherapy-based regimens in advanced non-small cell lung cancer. Cancer Research. 84(6_Supplement). 3819–3819.

Schenkel, Caroline, Suanna S. Bruinooge, Jeffrey Peppercorn, et al.. (2023). The state of cancer treatment trials in America: A comparison of counties with and without active trials by demography and social vulnerability.. JCO Oncology Practice. 19(11_suppl). 94–94. 1 indexed citations

He, Kai, David Berz, Shirish M. Gadgeel, et al.. (2023). MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. Journal of Thoracic Oncology. 18(7). 907–921. 20 indexed citations

Leal, Ticiana, David Berz, Igor I. Rybkin, et al.. (2022). 43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy. Annals of Oncology. 33. S19–S20. 13 indexed citations

Stenehjem, David D., Solomon J. Lubinga, Keith A. Betts, et al.. (2021). Treatment Patterns in Patients with Metastatic Non-Small-Cell Lung Cancer in the Era of Immunotherapy. Future Oncology. 17(22). 2940–2949. 14 indexed citations

Waterhouse, David, Jenny Lam, Keith A. Betts, et al.. (2021). Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer. Lung Cancer. 156. 41–49. 88 indexed citations

10.

Cowey, C. Lance, et al.. (2021). 1029TiP Phase II trial of pembrolizumab (pembro) and brentuximab vedotin (BV) in patients with metastatic solid malignancies after progression on prior programmed cell death protein (PD)-1 inhibitors (SGN35-033). Annals of Oncology. 32. S862–S862. 1 indexed citations

11.

Bustinduy, Amaya L., David Waterhouse, José Carlos Sousa-Figueiredo, et al.. (2016). Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy. mBio. 7(4). 61 indexed citations

12.

George, Ben, Karen Kelly, Amy Ko, et al.. (2016). Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) in solid tumors: results from the pancreatic cancer (PC) and non-small cell lung cancer (NSCLC) cohorts. Annals of Oncology. 27. vi363–vi363. 2 indexed citations

13.

Johnson, Melissa L., Volker Wacheck, Maen Hussein, et al.. (2016). A phase 2 study of LY3023414 and necitumumab after first-line chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi441–vi441. 3 indexed citations

14.

Blumenschein, George R., Jason C. Chandler, Edward B. Garon, et al.. (2016). PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC. Journal of Thoracic Oncology. 11(11). S307–S307. 4 indexed citations

15.

Weber, Jeffrey S., Laura A. Levit, Peter C. Adamson, et al.. (2014). American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment. Journal of Clinical Oncology. 33(3). 278–284. 81 indexed citations

16.

Zinner, Ralph, Coleman K. Obasaju, David R. Spigel, et al.. (2014). PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 10(1). 134–142. 120 indexed citations

17.

Hahn, Noah M., Walter M. Stadler, Robin Zoň, et al.. (2011). Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75. Journal of Clinical Oncology. 29(12). 1525–1530. 147 indexed citations

18.

Hainsworth, John D., David R. Spigel, Howard A. Burris, et al.. (2010). Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma. Journal of Clinical Oncology. 28(13). 2131–2136. 135 indexed citations

19.

Jalal, Shadia I., David Waterhouse, Martin J. Edelman, et al.. (2009). Pemetrexed plus Cetuximab in Patients with Recurrent Non-small Cell Lung Cancer (NSCLC): A Phase I/II Study from the Hoosier Oncology Group. Journal of Thoracic Oncology. 4(11). 1420–1424. 12 indexed citations

20.

Dyke, Gareth J., et al.. (2004). Three new landbirds from the early Paleogene of Denmark. ePrints Soton (University of Southampton). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact